Lmcg Investments LLC Cuts Position in AstraZeneca PLC (NASDAQ:AZN)

Lmcg Investments LLC lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 41.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 23,514 shares of the company’s stock after selling 16,845 shares during the period. Lmcg Investments LLC’s holdings in AstraZeneca were worth $1,541,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AZN. McClarren Financial Advisors Inc. raised its stake in shares of AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares during the last quarter. Capital Performance Advisors LLP purchased a new position in AstraZeneca during the 3rd quarter valued at about $28,000. Ashton Thomas Securities LLC acquired a new position in AstraZeneca during the third quarter worth about $45,000. Hollencrest Capital Management lifted its holdings in shares of AstraZeneca by 38.4% in the third quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock valued at $54,000 after purchasing an additional 192 shares in the last quarter. Finally, Versant Capital Management Inc grew its position in shares of AstraZeneca by 2,618.5% in the fourth quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock valued at $48,000 after purchasing an additional 707 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently issued reports on AZN. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Trading Up 2.0 %

Shares of AstraZeneca stock opened at $67.96 on Wednesday. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The business’s fifty day moving average is $66.14 and its two-hundred day moving average is $74.39. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The firm has a market cap of $210.75 billion, a PE ratio of 32.52, a P/E/G ratio of 1.05 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.87 earnings per share. Analysts anticipate that AstraZeneca PLC will post 4.12 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.